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ABSTRACT
Objectives: Several studies demonstrated that aldehyde dehydrogenase (ALDH) 
and CD44 are the most considered cancer stem cells (CSC) markers. However, a 
comparison between ALDH high cells and CD44+ cells have been previously described 
with no significant correlation. Indeed, the aim of the present research is to identify 
a superficial marker able to match with ALDH high cells population in freshly isolated 
human lung cancer cells.
Materials and Methods: This cross-sectional study analyzed the expression of 
ALDHhigh/low cells and the positivity for CD44 and epithelium cell adhesion molecule 
(EPCAM) antigens in surgical lung cancer tissues. The main approach was a 
cytofluorimetric analysis of ALDH expression and positivity for CD44/EPCAM on 
primary cell population obtained from 23 patients harboring NSCLC.
Results: There was a highly positive correlation between the expressions of 
ALDHhigh and CD44+/EPCAM+ cells, with a Pearson’s correlation coefficient equal to 
0.69 (95% CI 0.39–0.86; P = 0.0002), and Spearman’s correlation coefficient equal to 
0.52 (P = 0.0124). The average paired difference between the expression of ALDHhigh 
and CD44+/EPCAM+ cells was very close to 0, being 0.1% (SD 2.5%); there was no 
difference between these subpopulations in terms of means (95% CI = –1.0; 1.2%, 
P = 0.8464). These results highlight a strong similarity between ALDHhigh and CD44+/
EPCAM+ cells.
Conclusions: Our study is the first attempt which identifies a high correlation 
between the ALDHhigh and the CD44+/EPCAM+ cells, thus suggesting the possibility to 
use this superficial marker for future target treatments against lung cancer stem cells.
INTRODUCTION
The cancer stem cell (CSC) model was proposed 
over 30 years ago [1] and is a very important field of 
study in cancer research. The frequency of CSCs varies 
from 27% to 100% in highly tumorigenic cancers, such 
as hematopoietic and melanoma primary tumors, as well 
as in some cancer cell lines [2]. Although CSCs account 
for less than 1% of the total cells in solid tumors [3], they 
have several roles in tumor generation and progression, 
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such as in the capacity for self-renewal, asymmetric 
cell division, slow division kinetics, increased capacity 
of invasion, metastasis, tumor formation, proliferation, 
resistance to conventional chemotherapy, and radiotherapy 
and immunotherapy [4–7]. For the small amount of these 
cells inside the tumor, however, several studies have been 
conducted on the identification of CSC markers [8, 9].
The most considered CSC markers have been 
aldehyde dehydrogenase (ALDH), and CD44+ [10]. In 
particular, ALDH was described in 2010 by Sullivan et al. 
as a cancer stem cell marker in a panel of 11 non-small-
cell lung cancer (NSCLC) tumor samples, 45 NSCLC 
lines, and 7 small-cell lung cancer (SCLC) lines [11]. 
Additionally, this small population of CSCs was better 
identified using multiple markers [12]. In particular, 
Wang et al. in 2013 established a panel of lung cancer 
cell lines from primary tumors and characterized a small 
subpopulation as strongly positive for CD44 (CD44high), 
with the main population being weakly positive or 
negative for CD44. Co-expression of CD90 (CD90+) 
further narrowed down the putative stem cell population. 
This CD44 and CD90 positive subpopulation showed 
several CSC characteristics. In fact, the CD44high CD90+ 
subpopulation was considered a good candidate for a CSC 
marker [4].
In 2015, N. Zakaria et al. showed the putative 
lung CSC phenotypes of CD166+/CD44+ and CD166+/
EPCAM+ with multipotent characteristics of stem cells in 
lung adenocarcinoma cells (A549 and H2170) [8].
The identification of multiple markers is due to the 
complexity of highlighting the entire cancer stem cell 
population. Hence, a triple-positive marker, EPCAM+/
CD166+/CD44+, has recently been described in the 
human non-small cell lung cancer cell line [12].
Nevertheless, although ALDH is considered an 
intracellular enzyme and is the most used marker to 
identify CSCs in lung cancer [7, 11, 13], the scientific 
community has never correlated this intracellular marker 
with an epithelial marker, which may be very useful for 
targeting lung cancer stem cells. The aim of the present 
research was to compare the ALDHhigh cells with the 
double-positive CD44/EPCAM cells, in order to better 
define the superficial antigens of ALDHhigh cells. The 
use of superficial antigens may trigger new therapeutic 
approaches against CSCs in NSCLC.
RESULTS
Patients’ and specimens’ characteristics
The major clinical and demographic characteristics 
of the 24 patients enrolled from December 2017 to January 
2019 are reported in Table 1. The average age was 70.3 
years (SD 9.3, range 52 to 84); 62.5% were males, and 
all were smokers. Patients harboring stage I (37.5%) and 
stage III (37.5%) NSCLC were more prevalent than those 
harboring stage II (25.0%), whereas adenocarcinoma 
(75.0%) was more frequent than squamous cell carcinoma 
(25.0%). The surgical tumor specimens’ average weight 
was 1.3 grams (SD 1.9, range 0.1 to 9.6), and the average 
cellular yield was 33.8 million cells per gram (SD 35.9, 
range 7 to 150).
Cytofluorimetric analysis of ALDHhigh and 
CD44+/EPCAM+ in primary lung cancer cells
The putative CSCs were physically separated 
from the bulk parental tumor cells and recovered by 
fluorescence-activated cell sorting (FACS) according 
to the following gating strategy. Tumor cells were first 
identified based on their morphological parameters 
(forward scatter versus side scatter (FSC/SSC)), and 
ALDH activity was measured in the 7-AAD-negative 
cell subpopulation only. ALDHlow and ALDHhigh cells 
were selected and sorted. Results obtained in the main 
cytofluorimetric analysis are reported in Table 1. An 
ALDHhigh subpopulation was identified for all patients, 
and the average expression was 3.2% (SD 3.4%, range 
0.4% to 12.5%, with 69.6% of samples above 1%). A 
CD44+/EPCAM+ subpopulation was also identified in all 
samples, exhibiting an average expression equal to 3.1% 
(SD 2.5%, range 0.1% to 10.1%, with 82.6% of samples 
above 1%), similar to that of ALDHhigh cells (Figure 1). We 
also identified CD44+/EPCAM– and CD44–/EPCAM+ 
subpopulations with average expressions equal to 11.7% 
and 18.5% (SD 22.9% and 19.4%), respectively (Table 1) 
(Figure 1). The present results did not relevantly change 
if considering only the subgroup of 18 patients harboring 
adenocarcinoma (Supplementary Table 1, Supplementary 
Figure 1).
Relationship between ALDHhigh cancer stem-like 
cells and CD44+/EPCAM+ cells in primary lung 
cancer
As per the data reported in Table 2, there was a 
highly positive correlation between the expression of 
ALDHhigh cells and the expression of CD44+/EPCAM+ 
cells, with a Pearson’s linear correlation coefficient 
equal to 0.69 (95% CI 0.39–0.86; P = 0.0002), and 
Spearman’s rank correlation coefficient was equal to 0.52 
(P = 0.0124). Conversely, no correlation was observed 
between ALDHhigh and CD44+/EPCAM– cell 
subpopulations or between ALDHhigh and CD44–/
EPCAM+ cell subpopulations (Table 2).
The results of the assessment of the differences in 
the expression of ALDHhigh and CD44+/EPCAM+ cells are 
reported in Table 3. The average paired difference between 
the expression of ALDHhigh and CD44+/EPCAM+ cells 
was very close to 0, being 0.1% (SD 2.5%, range –5.2% 
to 5.0%). Moreover, 43.5% of samples had a difference 
of less than 1% between the expression of ALDHhigh cells 
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and the expression of CD44+/EPCAM+ cells, and 69.6% 
of samples had a difference of less than 2% between 
the expression of ALDHhigh cells and the expression of 
CD44+/EPCAM+ cells. Based on the paired t-test, there 
was no difference between these subpopulations in terms 
of means (P = 0.8464), and the 95% confidence interval 
for the paired difference was very narrow, ranging from 
–1.0% to 1.2%. Considering a target difference equal 
to 2% and based on the observed standard deviation for 
the difference between ALDHhigh and CD44+/EPCAM+ 
cells, the power of the paired t-test would be equal to 
95.9%; if considering a target difference of 1.5% or 1%, 
the corresponding powers would be equal to 79.2% and 
45.6%, respectively.
Finally, based on the linear regression model, 
we estimated that a 1% increase in CD44+/EPCAM+ 
expression yields on average a 0.9% increase in ALDH+ 
expression (95% CI 0.5%–1.3%). The estimated regression 
equation was very similar to the line representing equality 
in the expression of the 2 types of cells (Figure 2).
Cytofluorimetric analysis of ALDH high/low sorted 
cell subpopulations for the identification of 
CD44+/EPCAM+ cells
Primary lung cancer cells derived from a 65-year-
old male patient who had undergone surgery for stage 
IIB NSCLC were sorted by FACS to isolate ALDHhigh 
and ALDHlow cells. Subsequently, both ALDHhigh and 
ALDHlow cells were further analyzed for CD44+/EPCAM+ 
expression by FACS, setting a gate on 7AAD- and CD45. 
The results showed that a total of 49.4% of ALDHhigh cells 
were CD44+/EPCAM+, whereas only 2.6% of ALDHlow 
cells were CD44+/EPCAM+ (ratio 19:1) (Figure 3A).
CD44+/EPCAM+ sorted cells have the ability to 
form tumor spheres in vitro
Primary sorted CD44+/EPCAM+ cells derived 
from a 74-year-old male patient, who underwent surgery 
for stage IIIA NSCLC, were cultured to assess the growth 
Figure 1: Sorting of double-positive CD44+/EPCAM+ and negative CD44+/EPCAM– and CD44–/EPCAM+ cells. The 
gating strategy of a representative FACS analysis of a primary tumor cell suspension in 1 patient. We used 7-AAD to detect live cells and 
CD45 to exclude the hematopoietic cell populations.
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ability of these cells to form tumor spheres in vitro 
(Figure 4, Panel 1A–1C). At the time point of 2 days after 
the seeding, the CD44+/EPCAM+ cells had formed non-
adherent spheres in culture, and more than 50% of these 
tumor spheres were either small or medium in size, with 
a total area below 16.000 µm2. At the time point of 7 days 
after the seeding, there were no more spheres of 20.000 
µm2 or below in area, and the spheres belonging to the 
other classes had not increased in number since the time 
point of 2 days after the seeding. At the end point, 21 days 
after the seeding of the cells, only the tumor spheres of 
medium/large area remained, with spheres belonging to 
the classes of 16.000–32.000 µm2 in area and 32.000-
64.000 µm2 in area representing 50% of the total spheres 
in culture (Figure 4, Panel 2A–2C).
Gene expression of ALDH1A1 cancer stem 
cell marker according to positivity for CD44/
EPCAM
As an additional experiment, primary cells derived 
from a 76-year-old male patient, who underwent surgery 
for stage IA2 NSCLC, were co-stained for anti-CD44 
and anti-EPCAM antibodies for selection by cell sorting. 
The gene expression of ALDH1A1 was assessed in the 
CD44+/EPCAM+ cells in comparison with the other cell 
subpopulations sorted, the CD44+/EPCAM– cells and 
the CD44–/EPCAM+ cells. A fold change equal to 19.3 
times (ΔΔCt = –4.3) was found when comparing CD44+/
EPCAM+ cells to CD44+/EPCAM– cells, whereas a fold 
change equal to 3.0 times (ΔΔCt = –1.6) was observed 
when comparing CD44+/EPCAM+ cells to CD44–/
EPCAM+ cells. The ratio of these two fold changes was 
approximately 6.5:1 (Figure 3B).
DISCUSSION
Lung cancer has remained the most commonly 
occurring cancer globally. Traditional methods such as 
surgery, radiotherapy, and chemotherapy are treatment 
methods for lung cancer. Resistance to radiotherapy 
and chemotherapy and cancer relapse, however, 
remain challenging issues in lung cancer treatment. 
Chemoresistance is a major problem in the treatment of 
cancer patients, as cancer cells become resistant to the 
chemical substances used in treatment, thereby limiting 
the efficiency of chemo agents [14]. This resistance is 
attributable to a class of cells known as cancer stem cells. 
Table 1: Descriptive characteristics of the patients and specimens included in the study
Characteristics of patients All patients (n = 24)
Age (years)
mean ± SD 70.3 ± 9.3
median (range) 70 (52; 84)
Sex – M n (%) 15 (62.5%)
Smoker – Yes n (%) 24 (100.0%)
Adenocarcinoma n (%) 18 (75.0%)
Squamous cell carcinoma n (%) 6 (25.0%)
Stage - I n (%) 9 (37.5%)
Stage - II n (%) 6 (25.0%)
Stage - III n (%) 9 (37.5%)
Characteristics of specimens All samples (n = 24)
Weight (grams)
mean ± SD 1.3 ± 1.9
median (range) 0.8 (0.1; 9.6)
Cellular yield (million cells per gram)
mean ± SD 33.8 ± 35.9
median (range) 19.7 (7.0; 150.0)
Cytofluorimetric analysis All samples (n = 23)
ALDH+ (% on 7AAD- cells)
mean ± SD 3.2 ± 3.4%
median (range) 1.9% (0.4; 12.5%)
CD44+/EPCAM+ (% on 7AAD- cells)
mean ± SD 3.1 ± 2.5%
median (range) 2.6% (0.1; 10.1%)
CD44+/EPCAM– (% on 7AAD- cells)
mean ± SD 11.7 ± 22.9%
median (range) 2.5% (0.2; 86.0%)
CD44–/EPCAM+ (% on 7AAD- cells)
mean ± SD 18.5 ± 19.4%
median (range) 12.5% (0.0; 64.0%)
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In fact, accumulating evidence suggests that the cancer 
stem cell population is responsible for chemoresistance 
and cancer relapse, as CSCs have the ability to self-renew 
and to differentiate into heterogeneous lineages of cancer 
cells in response to chemotherapeutic agents [15, 16]. 
CSCs are also able to induce cell cycle arrest (quiescent 
state), which supports their ability to become resistant to 
chemotherapy and radiotherapy [17, 18].
Although successful cancer therapy abolishes the 
bulk of proliferating tumor cells, a subset of remaining 
CSCs can survive and promote cancer relapse due 
to their ability to establish higher invasiveness and 
chemoresistance [18, 19]. Understanding the features of 
CSCs will be important in establishing the foundation for 
a new era in the treatment of cancer. To achieve this goal, 
we strongly believe that an accurate identification of CSC 
antigens may be helpful in improving knowledge of this 
small but harmful population. This is why we conducted 
our experiments comparing ALDHhigh and CD44+/
EPCAM+ cell subpopulations.
The choice to use these markers derived from 
recent studies demonstrating that ALDH and CD44 are 
the most common CSC markers in many solid tumors 
[18, 20]. Nevertheless, in our previous study [15], we 
found comparable expression of ALDHhigh and CD44+ 
cells without a significant positive correlation, hence the 
necessity to add another antigen for identifying the cells 
that are the most similar to ALDHhigh cells, which are 
actually considered cancer stem cells [21, 22]. The choice 
to use EPCAM derived from a specific characteristic of 
this marker: it is an epithelial cell adhesion molecule, 
expressed by solid tumors of epithelial origin, such as 
non-small-cell lung cancer, breast cancer, or ovarian 
cancer [23]. Moreover, it is well recognized that EPCAM 
positive cells possess tumor-initiating potential, and 
EPCAM has already been used as a key marker of 
ovarian cancer stem cells [24]. These findings strongly 
support the notion that EPCAM is an ideal therapeutic 
target for ovarian cancer. In fact, various EPCAM 
antagonists have been developed as EPCAM-targeted 
Figure 2: Linear relation between the ALDHhigh and CD44+/EPCAM+ sorted cells. The red line represents the linear 
regression equation, considering ALDHhigh as the dependent variable and CD44+/EPCAM+ as the independent variable. The shaded area 
represents the confidence interval for the regression equation.
Table 2: Correlation of ALDHhigh cells expression with expression of CD44+ and EPCAM+ cells
Antigens
Pearson’s correlation Spearman’s correlation
r (95% CI) p r p
CD44+/EPCAM+ 0.69 (0.39; 0.86) 0.0002 0.52 0.0124
CD44+/EPCAM– 0.07 (–0.35; 0.48) 0.7429 0.19 0.3918
CD44–/EPCAM+ –0.29 (–0.63; 0.14) 0.1810 -0.30 0.1663
r = correlation coefficient; 95% CI = 95% confidence interval; p = p-value.
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antibodies serving as an effective treatment in both 
experimental models and clinical trials. From these 
findings, we decided to use CD44 together with EPCAM, 
comparing these selected cell subpopulations with the 
ALDHhigh cell subpopulation.
Interestingly, we found that there is a highly positive 
linear correlation between ALDHhigh cells and CD44+/
EPCAM+ cells. Furthermore, a very strong similarity 
between these cell subpopulations in terms of means was 
found, and their linear relationship was assessed as very 
close to equality. Conversely, we observed no correlation 
between ALDHhigh and CD44+/EPCAM– cells or between 
ALDHhigh and CD44–/EPCAM+ cells. These results 
suggested to us that the closest cells to ALDHhigh cells are 
CD44+/EPCAM+ cells. We regard this as a relevant result, 
since to the authors’ knowledge this is the first study that 
investigated and identified a robust correlation between 
these populations of cancer stem cells. Based on our 
observed results, this is the first study, which demonstrates 
that these two cancer stem cells populations seem to match 
closely with each other.
As performed previously [12], we decided to assess 
the tumor sphere formation ability of CD44+/EPCAM+ 
cells. We observed a growth of tumor spheres for up to 3 
weeks, with results that were similar to those previously 
recorded for ALDHhigh cells in terms of the number and 
size of spheres [7].
As proof of concept of the ALDH enrichment in 
the population identified by CD44+/EPCAM+ cells, we 
performed an additional experiment in which primary 
lung cancer cells were sorted for CD44/EPCAM antigens. 
The ALDH mRNA expression was evaluated by real-
time PCR in CD44+/EPCAM+, CD44+/EPCAM–, and 
CD44–/EPCAM+ cell subpopulations. Our results showed 
an abundant overexpression of the ALDH1A1 gene (fold 
change of 19.3) for CD44+/EPCAM+ cells versus CD44+/
EPCAM– cells; meanwhile, a slighter overexpression of 
the ALDH1A1 gene (fold change of 3) was observed for 
CD44+/EPCAM+ cells versus CD44–/EPCAM+ cells. 
Strong evidence also derived from the cytofluorimetric 
analysis of the ALDHhigh sorted cells stained for CD44/
EPCAM. Approximately 50% of the ALDHhigh sorted 
cells were CD44+/EPCAM+, whereas only 2.6% of the 
ALDHlow sorted cells were CD44+/EPCAM+.
Taken together, the results of the present research 
highlight a strong similarity between ALDHhigh and 
Figure 3: The assessment of CD44+/EPCAM+ cells in ALDHhigh sorted cells and their enrichment for the ALDH1A1 
cancer stem cell gene. (A) Approximately 50% of the ALDHhigh sorted cells were CD44+/EPCAM+ cells, whereas only 2.6% of the the 
ALDHlow cells were CD44+/EPCAM+ cells. (B) Gene expression analysis of ALDH1A1 assessed in CD44+/EPCAM+, CD44+/EPCAM–, 
and CD44–/EPCAM+ sorted cells. Histogram on the left axis showed a fold change equal to 19.3 times (ΔΔCt = –4.3) when comparing 
CD44+/EPCAM+ to CD44+/EPCAM– cells and a fold change equal to 3.0 times (ΔΔCt = –1.6) when comparing CD44+/EPCAM+ to 
CD44–/EPCAM+ cells.
Table 3: Analysis of equality of expressions of ALDHhigh and CD44+/EPCAM+ cells
All samples (n = 23) p-value
Δ (ALDHhigh minus CD44+/EPCAM+)
mean ± SD (95% CI) 0.1 ± 2.5% (–1.0 ; 1.2%)
0.8464
median (range) 0.0% (–5.2 ; 5.0%)
|Δ| ≤ 1% n (%) (cum %) 10 (43.5%) (43.5%)
|Δ| ≤ 2.5% n (%) (cum %) 6 (26.1%) (69.6%)
|Δ| ≤ 5% n (%) (cum %) 5 (21.7%) (91.3%)
|Δ| ≤ 7.5% n (%) (cum %) 2 (8.7%) (100.0%)
SD = standard deviation; Δ = difference between ALDH+ and CD44+/EPCAM+ expression; 95%CI = 95% confidence interval; cum % = cumulative 
percentage.
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CD44+/EPCAM+ cells, as suggested by cytofluorimetric 
analyses, tumor sphere-forming assays, and RT-PCR 
experiments.
The identification of surface markers in lung cancer 
can contribute to personalized medicine. Although there is 
still uncertainty in the identification of cancer stem cells 
especially in lung, the scientific community have pointed 
out their important role in prognosis and recurrence [25]. 
Furthermore, the identification of these markers may 
be helpful for a better epidemiological stratification of 
oncological patients. Hence, the identification of cancer 
stem cell markers should be considered as a crucial step 
in the development of novel cancer-specific molecular 
targeted therapies [25].
Our experiments, performed as proof of concept, 
showed that the superficial marker CD44+/EPCAM+ 
detected about half of the ALDHhigh cell population. 
These two populations seem to be very similar in terms of 
stemness gene expression as well as their capacity to make 
spheroids. In a recent study, MacDonagh et al. reported 
that ALDH1-positive cells can survive under cisplatin 
treatment [26]. This resistance to cancer treatments is daily 
confirmed in many oncologic patients. Although ALDH 
is nowadays considered an important marker for cancer 
stem cells as well as also for epithelial cancer cells [27] 
and that some clinical trials are running at the present time 
for analyzing ALDH-targeting treatments effects against 
cancer [28, 29], we strongly agree with the scientific 
community about the importance to identify markers, in 
order to develop target treatments against cancer stem cells 
[30–32]. In particular, with regards of our study, even if 
we hypothesized that the percentage of CD44+/EPCAM+ 
in ALDHhigh cell population would be less than 50% in 
other patients, the similarity of an intracellular marker 
highlighting ALDHhigh cell population with a superficial 
marker CD44+/EPCAM+ is a very important concept in 
terms of target treatment. In summary, our research is an 
important starting point for further studies that are needed 
Figure 4: Potential of tumor sphere formation by CD44+/EPCAM+ sorted cells. (1A–1C) representative tumor spheres from 
CD44+/EPCAM+ sorted cells at 2, 7, and 21 days. (2A–2C), tumor spheres exhibit the same number over time and increased area, as 
measurement at 2, 7, and 21 days indicates.
Oncotarget1552www.oncotarget.com
to better define the CD44+/EPCAM+ superficial marker 
highlighting lung cancer stem cells.
Limitations
A limitation of our study was that we did not 
perform formal sample size calculations for our main 
cytofluorimetric analysis. Nevertheless, the statistical 
power was calculated ex post and was satisfactory.
MATERIALS AND METHODS
The study was conducted by analyzing the 
expression of ALDHhigh/low cells and the positivity for 
CD44 and EPCAM antigens in a sample of surgical lung 
cancer tissue. The main approach was a cytofluorimetric 
analysis of ALDH expression and positivity for CD44/
EPCAM on primary cell population obtained from 23 
patients harboring NSCLC. Moreover, the following 
additional experiments were performed, on 1 patient 
each: 1) a cytofluorimetric analysis of CD44+/EPCAM+ 
on ALDHhigh/low sorted cell subpopulations; 2) a tumor 
sphere-forming assay on CD44+/EPCAM+ sorted cells; 
3) a real-time polymerase chain reaction (RT-PCR) for the 
ALDH1A1 mRNA expression on CD44+/EPCAM+ sorted 
cells.
Study design and sample size
The present study was a cross-sectional study and 
was conducted in accordance with the Strengthening 
the Reporting of Observational Studies in Epidemiology 
(STROBE) guidelines [33].
The outcomes evaluated in the study were the 
expressions of ALDHhigh, CD44+/EPCAM+, CD44+/
EPCAM–, and CD44–/EPCAM+ cells. The study 
primarily aimed at assessing the correlation and the 
pairwise difference between the expression of ALDHhigh 
and CD44+/EPCAM+ cells. Secondarily, correlations 
between ALDHhigh and CD44+/EPCAM– cells and between 
ALDH+ and CD44–/EPCAM+ cells were considered.
A formal calculation for sample size was not 
performed. A sample of patients who met the inclusion 
criteria during a 14-month timeframe was used. Statistical 
power calculations were performed ex post and were 
reported.
Study population
Overall, 24 patients met our inclusion criteria within 
those harboring NSCLC undergone major lung resection 
by lateral thoracotomy at the Division of Thoracic 
Surgery of Modena University Hospital (Italy) for stage 
I, II, or IIIA non-small-cell lung cancer (8th tumor, node, 
metastasis (TNM) staging system) in the period from 
December 2017 to January 2019 were included in the 
study. A main cytofluorimetric analysis was performed in 
23 patients; for one patient an additional cytofluorimetric 
analysis was added and in another one, the tumor sphere-
forming assay was carried out. The last patient enrolled 
was only included for the additional RT-PCR experiment. 
Inclusion criteria were aged between 18 and 85, R0 
resection, availability of formalin fixed, paraffin embedded 
surgery specimen from the primary tumor, and availability 
of fresh surgical specimen for cytofluorimetric analysis. 
Exclusion criteria were incomplete resection, unknown 
tumor, node, metastasis (TNM) status, synchronous 
tumors, and previous lung cancer.
Primary cells isolated from human lung cancer
Tumor tissues were obtained within 1 to 2 h after 
surgical removal, washed in sterile Dulbecco’s phosphate-
buffered saline (PBS) (L1825-BC – Merck Millipore, 
Italy), and mechanically minced into small pieces (2 to 
4 mm). Minced samples were digested using a tumor 
dissociation kit in a disposable gentle MACS™ C-Tube 
(Miltenyi Biotec, Italy) according to the manufacturer’s 
instructions. Samples were digested for 60 min at 37°C in 
a gentle MACS Octo dissociator, filtered through 70-μm 
sterile cell strainers, centrifuged at 300 × g for 5 min, and 
resuspended in a DMEM and HAM’S F12 media mixture 
(2:1) (Gibco) containing 50 IU/mL penicillin-streptomycin 
and 4 mM glutamine. Viable cells were counted using an 
optic phase-contrast microscope [7].
ALDEFLUOR assay
Single-cell suspensions of primary tumor cells 
were diluted in ALDEFLUOR assay buffer containing 
BODIPY-aminoacetaldehyde (STEMCELL Technologies, 
Vancouver, BC). The assay was performed according to 
the manufacturer’s protocol. Briefly, at least 5,000,000 
tumor cells were resuspended in ALDEFLUOR BUFFER 
(5 μl/106) and stained with ALDEFLUOR substrate. 
Immediately, 5 × 105 cells were transferred to a control tube 
containing 5 μl of diethylaminobenzaldehyde (DEAB), 
which is a specific inhibitor of ALDH. Control and test 
samples were incubated for 45 min at 37°C and protected 
from light. Cells were centrifuged at 300 × g for 5 min. The 
cell pellet was resuspended in 1 ml of ALDEFLUOR assay 
buffer [7, 13].
Cytofluorimetric analysis and cell sorting
Primary tumor cell suspensions were stained with 
ALDEFLUOR (Stem Cell) and allophycocyanin (APC)-
conjugated anti-CD45 (Becton Dickinson, Franklin 
Lakes, NJ), phycoerythrin (PE)‐conjugated anti-EPCAM 
(Becton Dickinson), and Brilliant Blue 515 (BB515) anti‐
CD44 (Becton Dickinson). An isotype control sample for 
each condition was used to exclude the autofluorescence 
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background. Cell morphology was evaluated using side 
scatter (SSC) and forward scatter (FSC). Dead cells were 
excluded using 7-amino-actinomycin D (7-AAD) staining. 
Both types of cells, ALDHhigh and double-positive CD44/
EPCAM, were analyzed and sorted. The gate was set 
based on ALDHhigh cells in 1 case and on CD45-negative-
CD44+/EPCAM+, CD45-negative cells-CD44+/EPCAM– 
and CD45-negative cells-CD44–/EPCAM+ in the other 
cases.
Cell sorting was performed using a FACSAria III 
(Becton Dickinson). The results were analyzed using 
fluorescence-activated cell sorting (FACS) Diva software 
(Becton Dickinson, Franklin Lakes, NJ). Sorted cells were 
directly lysed for gene expression analyses and seeded in 
culture for tumor sphere assay.
Tumor sphere-forming assay
A tumor sphere-forming assay on CD44+/
EPCAM+ cells was performed, as previously assessed by 
our research group for ALDHhigh cells [7]. The CD44+/
EPCAM+ single-cell suspension was seeded in 24 
ultralow attachment well plates. Cells were cultured in 
a mixture of serum-free Dulbecco’s modified Eagle’s 
medium (DMEM) and HAM’S F12 media (2:1) (Gibco) 
containing 50 IU/mL penicillin-streptomycin and 4 mM 
glutamine supplemented with 5 μg/ml insulin, 10 ng/ml 
epidermal growth factor (EGF), 20 ng/ml basic fibroblast 
growth factor (bFGF), 0.18 nM adenine, and 2 nM 
triiodotironin. The cells were cultured in 5% CO2 at 37°C 
for 3 weeks, and the media were replaced or supplemented 
with fresh growth factors twice per week. The entire well 
was digitally photographed using inverted phase-contrast 
microscopy (Zeiss Axioskop and Axiocam ICc3 color 
camera). All images were analyzed using the AxioVision 
software (Zeiss). The total number of spheres was counted, 
and the spheres’ areas were manually measured at 2, 7, and 
21 days from seeding.
Real-time PCR (RT-PCR)
Total cellular RNA was extracted from double-
positive CD44/EPCAM sorted cells using the RNeasy 
Mini Kit (Qiagen) according to the manufacturer’s 
instructions. Total RNA (2 µg) was reverse transcribed 
using the RevertAid™ First Strand cDNA Synthesis 
Kit (Thermo Scientific). Following cDNA synthesis, 
real-time PCR (RT-PCR) was performed in technical 
replicates for each sample using FAST SYBR™ Green 
detection chemistry (Applied Biosystems) on Step One 
instrument. Human ALDH1A1 and glyceraldehyde 
3-phosphate dehydrogenase (GAPDH) were amplified 
using gene-specific primers (ALDH1A1: forward primer 
5′- TGTTAGCTGATGCCGACTTG-3′, reverse primer 
5′-TTCTTAGCCCGCTCAACACT-3′; GAPDH: forward 
primer 5′-ACATCGCTCAGACACCATG-3′, reverse 
primer 5′TGTAGTTGAGGTCAATGAAGGG-3′). The 
forward and reverse primers were designed using IDT 
PrimerQuest1 (http://eu.idtdna.com/PrimerQuest/Home/
Index). The cycling parameters consisted of denaturation 
at 95°C for 10 min and 40 cycles of 15 sec at 94°C, 30 
sec at 60°C, and 1 min at 72°C, followed by a continuous 
melting curve.
Statistical analysis
The continuous variables were described in terms 
of mean, standard deviation (SD), median, and range. 
The categorical variables were described as absolute and 
percentage frequencies.
Expression of all cells was measured as the 
percentages of 7-AAD negative (7-AAD-) cells. We 
calculated the correlations of the expression of ALDHhigh 
cells with the expression of CD44+/EPCAM+, CD44+/
EPCAM–, and CD44–/EPCAM+ cells. Both Pearson’s 
linear correlation and Spearman’s rank correlation 
coefficients were considered. The difference between the 
expression of ALDHhigh cells and the expression of CD44+/
EPCAM+ cells was assessed using a paired t-test. The 
statistical power of the test was calculated ex post based 
on the observed standard deviation of the mean differences 
and considering 3 target differences equal to 2%, 1.5%, 
and 1%. A linear regression model that considers ALDHhigh 
cells expression as the dependent variable and CD44+/
EPCAM+ cells expression as the independent variable 
was used to assess the linear relationship of the two 
cells subpopulations. The regression line was reported 
graphically.
RT-PCR data were analyzed according to the 
methods described in [34]. The relative mRNA expression 
of ALDH+ cells was reported as Delta Delta Ct (ΔΔCt) 
and as fold changes (FC, equal to 2-ΔΔCt). Two relative 
mRNA expressions of ALDHhigh cells were calculated: 1) 
CD44+/EPCAM+ compared to CD44+/EPCAM– cells; 2) 
CD44–/EPCAM+ compared to CD44+/EPCAM+ cells.
The analyses were conducted using R 3.6.1 
statistical software (The R Foundation for Statistical 
Computing, Wien) at the 95% confidence level.
CONCLUSIONS
Our study is the first attempt toward the utility of a 
double superficial marker such as CD44+/EPCAM+ for 
the identification and further the targeting of lung cancer 
stem cells. This will be helpful for the setting of new 
treatments against lung cancer stem cells as well as also 
for a better control of the tumor growth.
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